April 2023 – Page 2 – Policy & Medicine

Policy and Medicine Compliance Update April 2023 Issue Features: DOJ’s updated Evaluation of Compliance Program guidance, and End of COVID-19 Health Emergency What Does that Mean for Compliance

Paris Appeals Court Overturns Huge Fine Against Novartis and Roche

FDA and HHS Need to Improve Tracking and Monitoring of IRBs

SAMHSA Publishes FAQs on Removal of X-Waiver Requirement

Novo Nordisk Suspended as ABPI Member for Serious Breaches of the Code of Practice

Pennsylvania Department of Human Services Amends Anti-Kickback Rule

FDA Issues Draft Guidance on Dosage and Administration Labeling Section

Transparency in Coverage Data Could Use Improvements

DEA Publishes Requirements for MATE Act One Time Requirement for Eight Hours of Substance Abuse Disorder Training

American Board of Surgery Announces Changes to MOC Credit Reporting